Article Text

Download PDFPDF
Original article
β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells
  1. Helena J M Smartt1,
  2. Alexander Greenhough1,
  3. Paloma Ordóñez-Morán2,
  4. Elena Talero3,
  5. Catherine A Cherry1,
  6. Catherine A Wallam1,
  7. Lee Parry4,
  8. Manal Al Kharusi1,
  9. Heather R Roberts1,
  10. John M Mariadason5,
  11. Alan R Clarke4,
  12. Joerg Huelsken3,
  13. Ann C Williams1,
  14. Chris Paraskeva1
  1. 1Cancer Research UK Colorectal Tumour Biology Research Group, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
  2. 2Cancer Stem Cell laboratory, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  3. 3Department of Pharmacology, School of Pharmacy, University of Seville, Seville, Spain
  4. 4Cardiff School of Biosciences, Life Sciences Building, Cardiff, UK
  5. 5Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
  1. Correspondence to Professor Chris Paraskeva, Cancer Research UK Colorectal Tumour Biology Research Group, School of Cellular and Molecular Medicine, University Walk, University of Bristol, Bristol BS8 1TD, UK; c.paraskeva{at}bristol.ac.uk

Abstract

Background Cyclooxygenase-2 (COX-2) overexpression in colorectal cancer increases levels of its pro-tumorigenic product prostaglandin E2 (PGE2). The recently identified colorectal tumour suppressor 15-prostaglandin dehydrogenase (15-PGDH) catalyses prostaglandin turnover and is downregulated at a very early stage in colorectal tumorigenesis; however, the mechanism responsible remains unclear. As Wnt/β-catenin signalling is also deregulated early in colorectal neoplasia, a study was undertaken to determine whether β-catenin represses 15-PGDH expression.

Methods The effect of modulating Wnt/β-catenin signalling (using β-catenin siRNA, mutant TCF4, Wnt3A or GSK3 inhibition) on 15-PGDH mRNA, protein expression and promoter activity was determined in colorectal cell lines by immunoblotting, qRT-PCR and reporter assays. The effect of β-catenin deletion in vivo was addressed by 15-PGDH immunostaining of β-catenin−/lox-villin-creERT2 mouse tissue. 15-PGDH promoter occupancy was determined using chromatin immunoprecipitation and PGE2 levels by ELISA.

Results The study shows for the first time that β-catenin knockdown upregulates 15-PGDH in colorectal adenoma and carcinoma cells without affecting COX-2 protein levels. A dominant negative mutant form of TCF4 (dnTCF4), unable to bind β-catenin, also upregulated 15-PGDH; conversely, increasing β-catenin activity using Wnt3A or GSK3 inhibition downregulated 15-PGDH. Importantly, inducible β-catenin deletion in vivo also upregulated intestinal epithelial 15-PGDH. 15-PGDH regulation occurred at the protein, mRNA and promoter activity levels and chromatin immunoprecipitation indicated β-catenin/TCF4 binding to the 15-PGDH promoter. β-catenin knockdown decreased PGE2 levels, and this was significantly rescued by 15-PGDH siRNA.

Conclusion These data suggest a novel role for β-catenin in promoting colorectal tumorigenesis through very early 15-PGDH suppression leading to increased PGE2 levels, possibly even before COX-2 upregulation.

  • 15-PGDH
  • β-catenin
  • PGE2
  • cyclooxygenase
  • colorectal cancer prevention
  • colorectal neoplasia
  • prostaglandins
  • cell biology
  • colon carcinogenesis
  • intestinal epithelium
  • gastrointestinal peptides
  • inflammatory bowel disease
  • cancer genetics
  • colorectal cancer
  • colorectal cancer genes
  • colorectal carcinoma
  • colorectal neoplasm
  • gene regulation
  • cell biology
  • cell death
  • cancer prevention
  • chemoprevention
  • cyclooxygenase-2
  • dietary fibre
  • butyrate

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding This work was supported by a Programme Grant (C19/A5301) from Cancer Research UK and by the John James Bristol Foundation.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Digest
    Emad El-Omar William Grady Alexander Gerbes